PEDIATRICS Vol. 99 No. 6 June 1997, pp. 819-824 (doi:10.1542/peds.99.6.819)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gregg, R. G.
Right arrow Articles by Splaingard, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gregg, R. G.
Right arrow Articles by Splaingard, M.
Related Collections
Right arrow Gastrointestinal Tract

PEDIATRICS Vol. 99 No. 6 June 1997, pp. 819-824

Newborn Screening for Cystic Fibrosis in Wisconsin: Comparison of Biochemical and Molecular Methods

Received Aug 6, 1996; accepted Oct 15, 1996.

Ronald G. Gregg*, Amy SimantelDagger , Philip M. FarrellDagger , Rebecca KoscikDagger , Michael R. KosorokDagger , Anita LaxovaDagger , Ronald Laessig§, Gary Hoffman§, David Hassemer§, Elaine H. Mischlerparallel , and Mark Splaingardparallel

From the * Waisman Center for Mental Retardation and Human Development; Dagger  Departments of Pediatrics and Biostatistics, § State Laboratory of Hygiene, University of Wisconsin-Madison, Madison, Wisconsin, and the parallel  Medical College of Wisconsin, Milwaukee, Wisconsin.

Objectives.  To evaluate neonatal screening for cystic fibrosis (CF), including study of the screening procedures and characteristics of false-positive infants, over the past 10 years in Wisconsin. An important objective evolving from the original design has been to compare use of a single-tier immunoreactive trypsinogen (IRT) screening method with that of a two-tier method using IRT and analyses of samples for the most common cystic fibrosis transmembrane regulator (CFTR) (Delta F508) mutation. We also examined the benefit of including up to 10 additional CFTR mutations in the screening protocol.

Methods.  From 1985 to 1994, using either the IRT or IRT/DNA protocol, 220 862 and 104 308 neonates, respectively, were screened for CF. For the IRT protocol, neonates with an IRT >= 180 ng/mL were considered positive, and the standard sweat chloride test was administered to determine CF status. For the IRT/DNA protocol, samples from the original dried-blood specimen on the Guthrie card of neonates with an IRT >= 110 ng/mL were tested for the presence of the Delta F508 CFTR allele, and if the DNA test revealed one or two Delta F508 alleles, a sweat test was obtained.

Results.  Both screening procedures had very high specificity. The sensitivity tended to be higher with the IRT/DNA protocol, but the differences were not statistically significant. The positive predictive value of the IRT/DNA screening protocol was 15.2% compared with 6.4% if the same samples had been screened by the IRT method. Assessment of the false-positive IRT/DNA population revealed that the two-tier method eliminates the disproportionate number of infants with low Apgar scores and also the high prevalence of African-Americans identified previously in our study of newborns with high IRT levels. We found that 55% of DNA-positive CF infants were homozygous for Delta F508 and 40% had one Delta F508 allele. Adding analyses for 10 more CFTR mutations has only a small effect on the sensitivity but is likely to add significantly to the cost of screening.

Conclusions.  Advantages of the IRT/DNA protocol over IRT analysis include improved positive predictive value, reduction of false-positive infants, and more rapid diagnosis with elimination of recall specimens.

Key words: cystic fibrosis, newborn screening, immunoreactive trypsinogen, population incidence, DNA testing.




This article has been cited by other articles:


Home page
 PediatricsHome page
A. M. Comeau, F. J. Accurso, T. B. White, P. W. Campbell III, G. Hoffman, R. B. Parad, B. S. Wilfond, M. Rosenfeld, M. K. Sontag, J. Massie, et al.
Guidelines for Implementation of Cystic Fibrosis Newborn Screening Programs: Cystic Fibrosis Foundation Workshop Report
Pediatrics, February 1, 2007; 119(2): e495 - e518.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Public HealthHome page
N. S. Green, S. M. Dolan, and T. H. Murray
Newborn Screening: Complexities in Universal Genetic Testing
Am J Public Health, November 1, 2006; 96(11): 1955 - 1959.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. E. van den Akker-van Marle, H. M. Dankert, P. H. Verkerk, and J. E. Dankert-Roelse
Cost-effectiveness of 4 Neonatal Screening Strategies for Cystic Fibrosis
Pediatrics, September 1, 2006; 118(3): 896 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
J Massie, L Curnow, N Tzanakos, I Francis, and C F Robertson
Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing
Arch. Dis. Child., March 1, 2006; 91(3): 222 - 225.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. H. Farrell, A. La Pean, and L. Ladouceur
Content of Communication by Pediatric Residents After Newborn Genetic Screening
Pediatrics, December 1, 2005; 116(6): 1492 - 1498.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. La Pean and M. H. Farrell
Initially Misleading Communication of Carrier Results After Newborn Genetic Screening
Pediatrics, December 1, 2005; 116(6): 1499 - 1505.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
N. S. Green, S. M. Dolan, and M. Oinuma
Implementation of Newborn Screening for Cystic Fibrosis Varies Widely Between States
Pediatrics, August 1, 2004; 114(2): 515 - 516.
[Full Text] [PDF]

Home page
 PediatricsHome page
A. M. Comeau, R. B. Parad, H. L. Dorkin, M. Dovey, R. Gerstle, K. Haver, A. Lapey, B. P. O'Sullivan, D. A. Waltz, R. G. Zwerdling, et al.
Population-Based Newborn Screening for Genetic Disorders When Multiple Mutation DNA Testing Is Incorporated: A Cystic Fibrosis Newborn Screening Model Demonstrating Increased Sensitivity but More Carrier Detections
Pediatrics, June 1, 2004; 113(6): 1573 - 1581.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
S. F. Dobrowolski, R. A. Banas, J. G. Suzow, M. Berkley, and E. W. Naylor
Analysis of Common Mutations in the Galactose-1-Phosphate Uridyl Transferase Gene: New Assays to Increase the Sensitivity and Specificity of Newborn Screening for Galactosemia
J. Mol. Diagn., February 1, 2003; 5(1): 42 - 47.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. J. Ciske, A. Haavisto, A. Laxova, L. Z. M. Rock, and P. M. Farrell
Genetic Counseling and Neonatal Screening for Cystic Fibrosis: An Assessment of the Communication Process
Pediatrics, April 1, 2001; 107(4): 699 - 705.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
P. M. Farrell, M. R. Kosorok, M. J. Rock, A. Laxova, L. Zeng, H.-C. Lai, G. Hoffman, R. H. Laessig, M. L. Splaingard, and the Wisconsin Cystic Fibrosis Neonatal Screening S
Early Diagnosis of Cystic Fibrosis Through Neonatal Screening Prevents Severe Malnutrition and Improves Long-Term Growth
Pediatrics, January 1, 2001; 107(1): 1 - 13.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
J. Sarles, S. Barthellemy, C. Férec, J. Iovanna, M. Roussey, J.-P. Farriaux, A. Toutain, J. Berthelot, N. Maurin, J.-P. Codet, et al.
Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 1999; 80(2): 118F - 122.
[Abstract] [Full Text]

Home page
 NEJMHome page
P. M. Farrell, M. R. Kosorok, A. Laxova, G. Shen, R. E. Koscik, W. T. Bruns, M. Splaingard, E. H. Mischler, and The Wisconsin Cystic Fibrosis Neonatal Screening S
Nutritional Benefits of Neonatal Screening for Cystic Fibrosis
N. Engl. J. Med., October 2, 1997; 337(14): 963 - 969.
[Abstract] [Full Text] [PDF]